DCF fair value estimate for Intensity Therapeutics: $0.87.
Get informed when a big investor buys or sells
+ Follow$0.87
Overvalued by 78.2% based on the discounted cash flow analysis.
Intensity Therapeutics's discounted cash flow stands at $0.87. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
Discounted cash flow values INTS by forecasting cash the business could generate and bringing those cash flows to present value. Stockcircle's latest estimate is $0.87, implying the shares look overvalued by about 78.2%. Pair DCF with P/E, growth, and balance-sheet metrics before making a decision.
The history chart shows how Intensity Therapeutics's DCF fair value evolved across reporting periods, while the comparison chart places INTS next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.